Hubert G. Leufkens - Search Results

Year	Number of Results
2002	14
2003	13
2004	9
2005	4
2006	11
2007	16
2008	16
2009	17
2010	14
2011	16
2012	20
2013	24
2014	16
2015	16
2016	21
2017	8
2018	2
2019	4
2020	5
2021	6
2022	5
2023	2
2024	1

1

Pharmacy-led pharmacovigilance: Ready for use or missed opportunity?

Leufkens HG. Leufkens HG. Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1562. doi: 10.1002/pds.4901. Epub 2019 Nov 12. Pharmacoepidemiol Drug Saf. 2019. PMID: 31714644 No abstract available.

2

Regulatory science: Regulation is too important to leave it to the regulators.

Leufkens HG. Leufkens HG. Br J Clin Pharmacol. 2020 Dec;86(12):2333-2334. doi: 10.1111/bcp.13917. Epub 2019 Apr 10. Br J Clin Pharmacol. 2020. PMID: 30968447 Free PMC article. No abstract available.

3

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN. Tetteh RA, et al. Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6. Drug Saf. 2017. PMID: 28130774 Free PMC article. Review.

4

Four scenarios for the future of medicines and social policy in 2030.

Leufkens HG, Kusynová Z, Aitken M, Hoekman J, Stolk P, Klein K, Mantel-Teeuwisse AK. Leufkens HG, et al. Drug Discov Today. 2022 Aug;27(8):2252-2260. doi: 10.1016/j.drudis.2022.03.018. Epub 2022 Mar 29. Drug Discov Today. 2022. PMID: 35364271 Free article. Review.

5

Traceability of biologicals: present challenges in pharmacovigilance.

Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Expert Opin Drug Saf. 2015. PMID: 25369769 Review.

6

Pharmacovigilance of biopharmaceuticals: challenges remain.

Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Giezen TJ, et al. Drug Saf. 2009;32(10):811-7. doi: 10.2165/11316550-000000000-00000. Drug Saf. 2009. PMID: 19722725 Review.

7

Extensions of indication throughout the drug product lifecycle: a quantitative analysis.

Langedijk J, Whitehead CJ, Slijkerman DS, Leufkens HG, Schutjens MH, Mantel-Teeuwisse AK. Langedijk J, et al. Drug Discov Today. 2016 Feb;21(2):348-55. doi: 10.1016/j.drudis.2015.11.009. Epub 2015 Dec 2. Drug Discov Today. 2016. PMID: 26657087 Review.

8

Today's challenges in pharmacovigilance: what can we learn from epoetins?

Ebbers HC, Mantel-Teeuwisse AK, Moors EH, Schellekens H, Leufkens HG. Ebbers HC, et al. Among authors: leufkens hg. Drug Saf. 2011 Apr 1;34(4):273-87. doi: 10.2165/11586350-000000000-00000. Drug Saf. 2011. PMID: 21417500 Review.

9

Orphan drug development across Europe: bottlenecks and opportunities.

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG. Heemstra HE, et al. Drug Discov Today. 2008 Aug;13(15-16):670-6. doi: 10.1016/j.drudis.2008.05.001. Epub 2008 Jun 24. Drug Discov Today. 2008. PMID: 18583178 Review.

10

Determinants for successful marketing authorisation of orphan medicinal products in the EU.

Putzeist M, Heemstra HE, Garcia JL, Mantel-Teeuwisse AK, Gispen-De Wied CC, Hoes AW, Leufkens HG. Putzeist M, et al. Drug Discov Today. 2012 Apr;17(7-8):352-8. doi: 10.1016/j.drudis.2011.10.027. Epub 2011 Nov 7. Drug Discov Today. 2012. PMID: 22094244 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

227 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year